ZEALAND PHARMA A/S

ZEAL
Real-time Estimate Cboe Europe - 10:40 2022-12-07 am EST
202.50 DKK +2.95%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Sales per Business
20202021
Peptide-based Medicines353.31100%292.57100%
DKK in Million
Sales per region
20202021
United States204.2057.8%239.6081.9%
Denmark149.1042.2%53.0018.1%
DKK in Million
Managers
Name Title
Adam Sinding Steensberg President & Chief Executive Officer
Henriette Wennicke Chief Financial Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. Mller Executive VP-Technical Development & Operations
Danilo Verge Head-Global Medical Affairs
David M. Kendall Chief Medical Officer
Michael John Owen Independent Director
Kirsten Aarup Drejer Vice Chairman
Alain H. Munoz Independent Director
Bernadette Mary Connaughton Independent Director
Shareholders
Name Equities %
Van Herk Investments BV 7,321,632 14.2%
Polar Capital LLP 3,508,141 6.81%
Credit Suisse Asset Management (Schweiz) AG 2,168,123 4.21%
Capital Research & Management Co. (World Investors) 1,787,654 3.47%
T. Rowe Price International Ltd. 1,347,328 2.62%
The Vanguard Group, Inc. 1,285,005 2.49%
Norges Bank Investment Management 1,038,127 2.02%
Handelsbanken Fonder AB 792,922 1.54%
Swedbank Robur Fonder AB 739,763 1.44%
Nykredit Bank A/S (Investment Management) 703,915 1.37%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ZEALAND PHARMA A/S-17.57%1 430
VERTEX PHARMACEUTICALS44.63%80 039
REGENERON PHARMACEUTICALS, INC.19.62%79 831
BIONTECH SE-37.31%39 277
WUXI APPTEC CO., LTD.-34.04%32 589
GENMAB A/S23.38%29 957
ARGENX SE18.17%21 685
BEIGENE, LTD.-30.76%19 482
NEUROCRINE BIOSCIENCES, INC.41.14%11 556
SAREPTA THERAPEUTICS, INC.33.37%10 543
LEGEND BIOTECH CORPORATION15.77%9 033
HALOZYME THERAPEUTICS, INC.40.21%7 623
KARUNA THERAPEUTICS, INC.73.24%6 900
ASCENDIS PHARMA A/S-10.31%6 742
EXELIXIS, INC.-5.80%5 377
PHARMAESSENTIA CORPORATION80.89%5 215
INTRA-CELLULAR THERAPIES, INC.1.68%5 040
REMEGEN CO., LTD.-39.22%4 703
CEREVEL THERAPEUTICS HOLDINGS, INC.-16.07%4 251
DENALI THERAPEUTICS INC.-31.70%4 137
MIRATI THERAPEUTICS, INC.-51.24%4 119
Brand Portfolio
ZEALAND PHARMA
ZEALAND PHARMA
More brands of Zealand Pharma A/S